Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC.
Chengxiang YiYayi HeHaoran XiaHelin ZhangPeng ZhangPublished in: OncoTargets and therapy (2019)
Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC.
Keyphrases
- early stage
- rectal cancer
- small cell lung cancer
- lymph node
- locally advanced
- advanced non small cell lung cancer
- clinical trial
- clinical practice
- end stage renal disease
- sentinel lymph node
- brain metastases
- prognostic factors
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- randomized controlled trial
- peritoneal dialysis
- study protocol
- open label